Back to companies

Fulcrum Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a clinical-stage biopharmaceutical company that develops therapies for genetically defined diseases. Its pipeline product is pociredir for the treatment of sickle cell disease (SCD). The company’s therapeutic areas include neuromuscular, muscular, hematologic, muscle, blood and central nervous system disorders. It also offers discovery programs for DBA and inherited aplastic anemias, novel HbF inducers, fibrotic disorders, and cardiomyopathies. Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Fulcrum Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Fulcrum Therapeutics Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address 26 Landsdowne Street, Cambridge, Massachusetts, 02139
Website www.fulcrumtx.com
Telephone 1 617 6518851
No of Employees 55
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange FULC (NASD)
EPS XYZ
Net Income (2024) XYZ -670% (2024 vs 2023)
Market Cap* $293.0M
Net Profit Margin (2023) XYZ 99.7% (2024 vs 2023)
   
* As of and is in US$
View Fulcrum Therapeutics Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Fulcrum Therapeutics Inc premium industry data and analytics

30+

Catalyst Calendar

Proactively evaluate Fulcrum Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

12+

Pipeline Drugs

Identify which of Fulcrum Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

11+

Clinical Trials

Determine Fulcrum Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline Product:
Pociredir: Sickle Cell Disease (SCD)
Understand Fulcrum Therapeutics Inc portfolio and identify potential areas for collaboration Understand Fulcrum Therapeutics Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Fulcrum Therapeutics Inc Ionis Pharmaceuticals Inc Global Blood Therapeutics Inc Acceleron Pharma Inc Genetix Biotherapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Cambridge Carlsbad San Francisco Rahway Somerville
State/Province Massachusetts California California New Jersey Massachusetts
No. of Employees 55 1,402 457 312 248
Entity Type Public Public Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Kate Haviland Chairman Executive Board 2022 50
Alex C. Sapir Director; Chief Executive Officer; President Executive Board 2023 59
Alan Musso Chief Financial Officer Senior Management 2023 64
Curtis Oltmans Chief Legal Officer; Head - External Affairs Senior Management 2025 62
Bobby Riehle, Ph.D. Head - Program Strategy; Vice President Senior Management 2025 -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Fulcrum Therapeutics Inc key executives to enhance your sales strategy Gain insight into Fulcrum Therapeutics Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?